Cardiovascular Calcification Pipeline, Clinical Trials, and Key Companies – Sanifit, Inositec, Sanofi, Dong-A ST

DelveInsight’s, “Cardiovascular Calcification Pipeline Insight, 2023,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Cardiovascular Calcification pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

(United States, Nevada, Las Vegas), DelveInsight’s, “Cardiovascular Calcification Pipeline Insight, 2023,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Cardiovascular Calcification pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Cardiovascular Calcification Pipeline Report

Over 6+ companies and 6+ pipeline drugs in Cardiovascular Calcification are in various stages of development, and their anticipated acceptance in the Cardiovascular Calcification market would significantly increase market revenue.

Leading Cardiovascular Calcification companies developing novel drug candidates to improve the Cardiovascular Calcification treatment landscape include Sanifit, Inositec, Sanofi, Dong-A ST, and many others

Promising Cardiovascular Calcification pipeline therapies in various stages of development include SNF 472, INS-3001, and many others

Cardiovascular Calcification Overview

Cardiovascular calcification is a process in which mineral deposits form in vessel walls and heart valve leaflets and can lead to tissue stiffening, plaque rupture, and heart failure. Several biological processes contribute to cardiovascular calcification, including extracellular vesicle release, matrix remodeling, loss of mineral-deposition inhibition, impaired mineral resorption, oxidative stress, mitochondrial dysfunction, inflammation, and stem and progenitor cell programs. It is a commonly observed but incompletely understood mechanism of increased atherosclerotic plaque instability and accelerated aortic valve stenosis.

Cardiovascular Calcification Pipeline Analysis: Drug Profile

SNF 472: Sanifit

SNF472 is a novel small molecule, and a selective and potent inhibitor of hydroxyapatite (HAP) crystallization, the final common pathway that leads to vascular calcification. Sanifit’s SNF 472 blocks calcification, with action independent of Ca/Phosphate levels.

INS-3001: Inositec

INS-3001 is a cardiovascular calcification inhibitor, based on myo-inositol hexaphosphate (IP6). It is being developed to treat a number of diseases driven by cardiovascular calcification, including aortic valve stenosis. The molecule has demonstrated the ability to significantly inhibit the calcification process in preclinical studies.

Discover more about the emerging Cardiovascular Calcification drugs @ Cardiovascular Calcification Treatment Drugs

Cardiovascular Calcification Pipeline Therapies and Key Companies

SNF 472: Sanifit

INS-3001: Inositec

NS-3001: Inositec

And many others

Cardiovascular Calcification Pipeline Therapeutics Assessment

Phases

DelveInsight’s Report covers around 33+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued and inactive candidates

Route of Administration

Route of Administration

Cardiovascular Calcification pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Scope of the Cardiovascular Calcification Pipeline Report

Coverage: Global

Key Cardiovascular Calcification Companies: Sanifit, Inositec, Sanofi, Dong-A ST and many others

Key Cardiovascular Calcification Pipeline Therapies: SNF 472, INS-3001, and many others

Find out more about the Cardiovascular Calcification treatment options in development @ Cardiovascular Calcification Clinical Trials

Table of Contents

1. Cardiovascular Calcification Introduction

2. Cardiovascular Calcification Executive Summary

3. Cardiovascular Calcification Overview

4. Cardiovascular Calcification Pipeline Therapeutics

5. Cardiovascular Calcification Late-Stage Products (Phase III)

6. Cardiovascular Calcification Mid-Stage Products (Phase II)

7. Cardiovascular Calcification Early Stage Products (Phase I/II)

8. Cardiovascular Calcification Preclinical Stage Products

9. Cardiovascular Calcification Discovery Stage Products

10. Cardiovascular Calcification Therapeutic Assessment

11. Cardiovascular Calcification Inactive Products

12. Cardiovascular Calcification Collaborations Assessment- Licensing / Partnering / Funding

13. Cardiovascular Calcification Unmet Needs

14. Cardiovascular Calcification Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Adya Kaul

Email: [email protected]

Phone: 919650213330

Address:304 S. Jones Blvd #2432

City: Las Vegas

State: Nevada

Country: United States

Website: https://www.delveinsight.com/consulting/due-diligence-services

Source: www.abnewswire.com

.